Hemispherx Biopharma Incorporates Continuous Manufacturing at its NJ Facility
The upgrades will offer the opportunity for higher product yields and higher purity levels.
Hemispherx Biopharma announced in March 2, 2015 that the company is upgrading its New Brunswick, NJ, facility to incorporate new continuous manufacturing capabilities. The company, which produces a natural alpha interferon (interferon alfa-n3, trade name Alferon N) for the treatment of refractory or recurring external genital warts, halted the manufacture of its drug in 2008 because of high labor costs and low capacity, which the company said in a release significantly limited the commercialization potential of the treatment.
After $8 million in facility upgrades, the company integrated continuous manufacturing throughout the process. The company scaled up from hundreds of small flasks to a 600-L bioreactor, effectively eliminating approximately 80% of the manpower previously needed for this part of the process. The change also led to “improved cost efficiency, enhanced yields, real-time process monitoring, flexibility to tailor batch size for lean manufacturing, and improved operational safety,” according to the statement.
While the process improvement may improve cost efficiency, the company said that FDA will need to reaffirm the amended biologic license application for the facility before the sales of Alferon N can commence through its distributor, Armada Health Care.
Source: Hemispherx Biopharma
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
